ResearcherCapital Medical UniversityNo recent work listed
Dong Zhang
Matched on ORCID iD 0000-0002-3404-5173; OpenAlex author ID A5100366103. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2011: 2 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper
Papers 6
- CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s40659-017-0149-0↗
- β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Co-author DOI 10.18632/oncotarget.5677↗
- Association between vitamin C intake and the risk of pancreatic cancer: a meta-analysis of observational studies. Co-author DOI 10.1038/srep13973↗
- Pancreaticoduodenectomy combined with vascular resection and reconstruction for patients with locally advanced pancreatic cancer: a multicenter, retrospective … Co-author DOI 10.1371/journal.pone.0070340↗
- β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction. Co-author DOI 10.1016/j.ejphar.2011.04.055↗
- β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway. Co-author DOI 10.1186/1476-4598-10-146↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yi Cai · 1 shared paper, 2018 · strength 0.12
- Peng Shen · 1 shared paper, 2018 · strength 0.12
- Qingyong Ma · 3 shared papers, 2011–2016 · strength 0.11
- Paper β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. DOI 10.18632/oncotarget.5677↗
- Paper β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptos… DOI 10.1016/j.ejphar.2011.04.055↗
- Paper β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway. DOI 10.1186/1476-4598-10-146↗
- Erxi Wu · 3 shared papers, 2011–2016 · strength 0.11
- Paper β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. DOI 10.18632/oncotarget.5677↗
- Paper β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptos… DOI 10.1016/j.ejphar.2011.04.055↗
- Paper β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathway. DOI 10.1186/1476-4598-10-146↗
- Zheng Wu · 2 shared papers, 2013–2016 · strength 0.08
- Paper β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. DOI 10.18632/oncotarget.5677↗
- Paper Pancreaticoduodenectomy combined with vascular resection and reconstruction for patients with locally advanced pancreat… DOI 10.1371/journal.pone.0070340↗
- Zheng Wang · 2 shared papers, 2011–2016 · strength 0.08
- Hua Fan · 1 shared paper, 2015 · strength 0.06
- Qiang He · 1 shared paper, 2015 · strength 0.06
- Xiongwei Huo · 1 shared paper, 2016 · strength 0.05
- Jianjun Lei · 1 shared paper, 2016 · strength 0.05
- Ligang Nan · 1 shared paper, 2016 · strength 0.05
- Zhengdong Jiang · 1 shared paper, 2016 · strength 0.05
- Jiguang Ma · 1 shared paper, 2016 · strength 0.05
- Wanxing Duan · 1 shared paper, 2016 · strength 0.05
- Qinhong Xu · 1 shared paper, 2016 · strength 0.05
- Xuqi Li · 1 shared paper, 2016 · strength 0.05
- Leida Zhang · 1 shared paper, 2013 · strength 0.03
- Qilong Chen · 1 shared paper, 2013 · strength 0.03
- Ping Bie · 1 shared paper, 2013 · strength 0.03
- Qi Wang · 1 shared paper, 2013 · strength 0.03
- Tieying He · 1 shared paper, 2013 · strength 0.03
- Yi Gong · 1 shared paper, 2013 · strength 0.03
- Huaizhi Wang · 1 shared paper, 2013 · strength 0.03
- Tao Shan · 1 shared paper, 2011 · strength 0.03
- Han Liu · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.